Financial Performance - The company's operating revenue increased by 15.08% year-on-year, primarily due to a surge in demand for heat-clearing and detoxifying drugs, resulting in a significant increase in sales compared to the previous year[19]. - The revenue from the pharmaceutical formulation business grew by 91.04% year-on-year, driven by successful bids in inter-provincial alliance procurement and the continuous enrichment of the traditional Chinese medicine product pipeline[19]. - The net profit attributable to shareholders decreased by 12.9 million yuan, mainly due to increased R&D personnel in research branches and higher investments in high-end formulations and improved new drug projects[19]. - The net cash flow from operating activities decreased by 21.62 million yuan year-on-year, attributed to increased personnel reserves and R&D investments in the pharmaceutical R&D service business[19]. - Basic earnings per share for the reporting period were -0.0677 yuan, compared to -0.0452 yuan in the same period last year[19]. - The diluted earnings per share for the reporting period were -0.0677 yuan, consistent with the basic earnings per share[19]. - The weighted average return on net assets was -2.49%, compared to -1.51% in the same period last year[19]. - The weighted average return on net assets, after deducting non-recurring gains and losses, was -2.62%, compared to -0.91% in the same period last year[19]. - The net profit attributable to shareholders was a loss of ¥38,331,796.75, compared to a loss of ¥25,432,310.28 in the previous year, indicating a worsening financial performance[20]. - The net cash flow from operating activities was a negative ¥88,001,824.00, compared to a negative ¥66,380,836.05 in the same period last year, reflecting increased cash outflows[20]. - The total assets decreased by 5.69% to ¥3,395,367,101.76 from ¥3,600,184,129.95 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 9.65% to ¥1,418,871,940.83 from ¥1,570,479,281.96 at the end of the previous year[20]. - The company achieved a revenue of 993.91 million yuan in the reporting period, representing a year-on-year growth of 15.08%[42]. - The pharmaceutical formulation business focused on brand building and product structure enhancement, leading to increased market share and sales growth in key products such as Danshen oral liquid and pediatric cough syrup[42]. - The company reported a total comprehensive loss of ¥79,162,210.83 for the first half of 2023, compared to a loss of ¥29,807,692.69 in the previous year[139]. - The company reported a significant increase in sales expenses, which rose to ¥99,791,558.32, up 42.9% from ¥69,823,969.20 in the previous year[134]. Research and Development - Research and development expenses surged by 77.46% to ¥79,750,330.93, up from ¥44,939,144.73, indicating a significant investment in new product development[50]. - The company has 199 ongoing research projects, with 20 submitted for registration, 4 obtaining production registration, and 2 passing consistency evaluations during the reporting period[44]. - The company launched 29 new generic drug projects and 14 improved new drug projects in 2023, with a total of 151 ongoing independent research projects by the end of the reporting period[46]. - The company’s clinical CRO services include comprehensive support for clinical research, from protocol design to data management and statistical analysis[29]. - The company is leveraging its technological platform and investment cooperation to build a comprehensive lifecycle management service system for pharmaceuticals[29]. - The company is actively investing in high-quality projects within the healthcare sector, while remaining vigilant about external economic and regulatory changes that could impact investment returns[71]. Market Position and Strategy - The company operates in the pharmaceutical manufacturing and R&D services sectors, focusing on traditional Chinese medicine and various drug formulations[24]. - The company has over 700 varieties and 1,100 specifications of traditional Chinese medicine pieces, enhancing its competitive edge through value-added services[25]. - The sales model includes a combination of distribution and direct sales, with a marketing network established across more than 30 provinces in China[27]. - The company emphasizes a transparent and safe medication process through technology integration in its traditional Chinese medicine services[28]. - The company has been recognized as one of the "Top 100 Chinese Pharmaceutical Enterprises" and has received multiple honors, including being named a key leading enterprise in Henan Province for 2022-2024[35]. - The company is positioned to benefit from the increasing demand for CRO services, with an expected investment in pharmaceutical R&D in China reaching USD 47.6 billion by 2024, including USD 32.1 billion for clinical stage R&D[34]. Financial Management and Investments - The company completed the establishment of a 400 million yuan pharmaceutical industry fund, with an initial investment of 120 million yuan, to enhance capital operation capabilities[46]. - The company has received 7 domestic patent authorizations during the reporting period, including 3 invention patents[46]. - The company is actively expanding its investment opportunities in the healthcare industry, linking with market investment institutions to explore new growth points[46]. - The company has implemented a comprehensive quality control system in production, adhering to GMP requirements and enhancing operational efficiency[43]. - The company has maintained a 100% compliance rate in external product inspections, ensuring a strong market reputation[40]. Environmental and Social Responsibility - The company is listed as a key pollutant discharge unit in Zhengzhou for 2023, focusing on water environment management[82]. - The company reported a chemical oxygen demand (COD) discharge of 0.91322 tons in the first half of 2023, well below the permitted limit of 100 mg/l[84]. - The company has established an emergency response plan for environmental incidents, updated in May 2022[88]. - The company has implemented a self-monitoring scheme for environmental pollutants, with third-party monitoring confirming compliance with discharge standards[89]. - The company invested 334,600 yuan in poverty alleviation and rural revitalization projects, benefiting 173 individuals through industry and employment support[99]. Corporate Governance and Compliance - The company has committed to not engaging in any competitive activities with Tai Long Pharmaceutical and its subsidiaries during the reporting period[101]. - The company has ensured the independence of Tai Long Pharmaceutical's operations, maintaining separate personnel, assets, finances, and business[102]. - The company will not utilize its shareholder status to seek preferential treatment for itself or its affiliates in business dealings with Tai Long Pharmaceutical[101]. - The company has established a commitment to avoid competition with Tailong Pharmaceutical in any form within or outside China[105]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant overdue debts[107]. Shareholder Information - The company had 56,015 common stock shareholders as of the end of the reporting period[118]. - The largest shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd., held 14.37% of the shares, totaling 82,441,168 shares[120]. - Shareholder Wu Lan reduced his holdings by 5,842,200 shares, holding a total of 28,694,296 shares, representing 5.00%[120]. - The company reported a capital increase of 42,067,787.15 CNY from owner contributions during the current period[155]. - The total capital reserve at the end of the period is 750,255,579.20 CNY, which remains stable compared to the previous period[155]. Risk Management - The company faces significant industry policy risks due to the evolving regulatory landscape in the pharmaceutical sector, which has intensified market competition[68]. - Quality risk management is a priority, with the implementation of a comprehensive quality traceability system to ensure drug safety and efficacy throughout the production process[70]. - Research and development risks are acknowledged, with a commitment to enhancing the R&D team and decision-making processes to mitigate potential project delays and failures[71]. - The company is closely monitoring raw material prices and supply risks, which are influenced by various factors, including climate and environmental regulations, to manage operational costs effectively[70].

Group 1: Event Details - The event is scheduled for May 18, 2023, from 16:00 to 17:20 [1] - It will be held online via "全景·路演天下" platform [1] - The theme of the event is "Sincere Communication, Delivering Value" [1] Group 2: Participants - The attendees include General Manager Mr. Luo Jianchao, Board Secretary Ms. Feng Haiyan, and Financial Officer Mr. Zhao Hailin [1] - Participation may be adjusted due to special circumstances [1] Group 3: Company Commitment - The board guarantees the announcement's content is free from false records, misleading statements, or significant omissions [1] - The board takes legal responsibility for the truthfulness, accuracy, and completeness of the content [1]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 560,317,916.01, representing a year-on-year increase of 32.69%[3] - The net profit attributable to shareholders for Q1 2023 was CNY 3,682,566.68, reflecting a growth of 58.07% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 3,452,841.10, an increase of 40.91% year-on-year[3] - The basic earnings per share for Q1 2023 was CNY 0.0065, up by 58.54% from the previous year[3] - The company reported a net profit of CNY 201,783,788.37 for the first quarter of 2023, compared to CNY 186,609,951.83 in the first quarter of 2022, an increase of 8.1%[13] - The net profit for Q1 2023 was approximately ¥3.29 million, compared to ¥2.17 million in Q1 2022, representing a 51.8% increase[17] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3,572,512,646.95, a decrease of 0.77% from the end of the previous year[4] - The total assets of the company as of March 31, 2023, were CNY 3,572,512,646.95, a slight decrease from CNY 3,600,184,129.95 at the end of 2022[12] - The total liabilities decreased to CNY 1,975,922,301.14 as of March 31, 2023, from CNY 1,986,099,689.13 at the end of 2022, a reduction of 0.6%[13] - The equity attributable to shareholders at the end of Q1 2023 was CNY 1,553,379,373.18, down by 1.09% compared to the end of the previous year[4] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was CNY -92,268,340.56, representing a decrease of 39.29% year-on-year[3] - Cash flow from operating activities showed a net outflow of approximately ¥92.27 million in Q1 2023, an improvement from a net outflow of ¥151.97 million in Q1 2022[19] - Investment activities resulted in a net cash outflow of approximately ¥19.64 million in Q1 2023, compared to a net inflow of ¥63.11 million in Q1 2022[19] Shareholder Information - The company had a total of 62,349 common shareholders at the end of the reporting period[6] - The top shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., held 82,441,168 shares, accounting for 14.37% of the total shares[7] Operational Metrics - The company's cash and cash equivalents decreased to CNY 248,462,111.96 as of March 31, 2023, down from CNY 311,383,783.24 at the end of 2022, a decline of 20.1%[11] - Accounts receivable increased to CNY 744,735,581.99 as of March 31, 2023, compared to CNY 709,294,055.62 at the end of 2022, reflecting a growth of 5.0%[11] - The company's inventory as of March 31, 2023, was CNY 433,230,308.30, down from CNY 450,488,977.16 at the end of 2022, a decrease of 3.8%[11] - Non-current assets totaled CNY 1,589,611,259.02 as of March 31, 2023, compared to CNY 1,568,943,854.70 at the end of 2022, an increase of 1.3%[12] Research and Development - The company incurred research and development expenses of approximately ¥24.19 million in Q1 2023, compared to ¥19.58 million in Q1 2022, marking a 23.5% increase[16] Strategic Initiatives - The company established a pharmaceutical industry fund with a total scale of CNY 400 million, with an initial investment of CNY 120 million completed in January 2023[10] - The company is actively linking with market investment institutions and industry resources to expand its upstream and downstream industrial chain[10] Sales Performance - The company reported a significant increase in sales revenue from goods and services, totaling approximately ¥490.86 million in Q1 2023, compared to ¥355.72 million in Q1 2022, reflecting a 38% increase[18] - Total operating costs for Q1 2023 were approximately ¥558.03 million, up from ¥411.80 million in the same period last year, reflecting a 35.5% increase[16]

证券代码：600222 证券简称：太龙药业 公告编号：临 2023-020 河南太龙药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 7 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 10 日下午 15:00-16:30 举行 2022 年度业绩说明会，就投资者关心的问 题进行交流。 一、 说明会类型 本次业绩说明会以视频录播结合网络文字互动的形式召开，公司 河南太龙药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 04 月 28 日(星期五) 至 05 月 09 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 600222@taloph.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 会议召开时间：2023 年 05 月 10 日(星期三) 下午 15: ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,960,694,309.41, representing a 22.20% increase compared to CNY 1,604,516,940.00 in 2021[20]. - The net profit attributable to shareholders of the listed company was a loss of CNY 72,140,214.59, a decrease of 1,303.26% from a profit of CNY 5,995,375.55 in 2021[20]. - The net cash flow from operating activities was a negative CNY 124,405,873.93, down 224.84% from CNY 99,655,159.11 in 2021[21]. - The total assets at the end of 2022 were CNY 3,600,184,129.95, a decrease of 4.85% from CNY 3,783,772,407.22 at the end of 2021[21]. - The net assets attributable to shareholders of the listed company decreased by 5.42% to CNY 1,570,479,281.96 from CNY 1,660,509,428.09 at the end of 2021[21]. - Basic and diluted earnings per share were both -0.1283 yuan, reflecting a significant decrease compared to 0.0107 yuan in the previous year[22]. - The weighted average return on equity was -4.31%, down from 0.37% in the previous year, indicating a decline in profitability[22]. - The gross profit margin decreased by 4.77 percentage points to 24.04% compared to the previous year[66]. - The total revenue for the year 2022 was approximately CNY 1.95 billion, with a gross margin of 24.04%, reflecting a decrease of 4.77 percentage points compared to the previous year[69]. Revenue Segments - The company's operating revenue increased by 22.20% year-on-year, with traditional Chinese medicine segment revenue growing by 29.62% and pharmaceutical formulation revenue increasing by 19.04%[22]. - The revenue from traditional Chinese medicine oral liquids increased by 19.88% year-on-year, reaching approximately CNY 514.4 million, but the gross margin decreased by 5.05 percentage points to 44.29%[69]. - The revenue from Chinese herbal pieces grew by 29.62% year-on-year, totaling approximately CNY 942.4 million, with a stable gross margin of 11.92%[69]. - The revenue from pharmaceutical research and development services remained flat, but the gross margin decreased significantly by 15.31 percentage points to 32.05% due to increased project costs[69]. - The company’s revenue from the cardiovascular system segment was 5,089.73 million RMB, with a gross margin of 83.57%, reflecting a decrease of 3.28% from the previous year[100]. - The company’s revenue from the digestive system segment was 1,473.67 million RMB, with a gross margin of 65.36%, showing a slight increase of 0.56% compared to the previous year[100]. Research and Development - The company is focusing on the development of new products and technologies, although specific details were not disclosed in the report[19]. - The company has 191 research projects, with 43 submitted for registration and 16 obtaining production registration certificates[36]. - The company launched 61 new independent research projects in 2022, with 110 projects still in the pipeline[38]. - The company reported a research and development investment of 6.36% of operating revenue, which is lower than the industry average of 10.00%[106]. - The company’s R&D investment amounted to 6,029.68 million RMB at the end of the reporting period, an increase of 4,457.21 million RMB from the beginning of the period[115]. - The company is actively pursuing the introduction of new traditional Chinese medicine products and enhancing its investment in the development of improved new drugs[23]. - The company has established partnerships with well-known universities and research institutions to enhance its research capabilities in traditional Chinese medicine[101]. Market Strategy and Competitiveness - The company plans to enhance its market competitiveness by increasing sales promotion efforts in key regions and investing in the research of classic Chinese medicine formulas[23]. - The company aims to expand its market presence and enhance customer loyalty through deeper service offerings and strategic partnerships in the pharmaceutical sector[54]. - The company is focusing on diversifying its drug research technology platforms and increasing the number of self-initiated projects, which may impact short-term profitability but is expected to yield results in the future[23]. - The company plans to expand its product range and improve brand influence through differentiated marketing strategies and academic promotion[126]. - The company is committed to strengthening its internal control systems and risk management to ensure sustainable growth[125]. Corporate Governance and Management - The company has conducted 5 shareholder meetings and 13 board meetings during the reporting period, ensuring compliance with governance standards[136]. - The company has implemented a third employee stock ownership plan to enhance performance evaluation and incentive mechanisms for management[137]. - The company has a clear organizational structure that operates independently and effectively, adhering to legal and regulatory requirements[139]. - The company has established a compensation and assessment committee under the board to oversee the remuneration of directors and senior management[153]. - The company emphasizes transparency in its remuneration practices, with clear guidelines for performance evaluation and payment schedules[153]. Environmental Responsibility - The company invested 3.22 million yuan in environmental protection during the reporting period[184]. - The company’s subsidiary, Yu Zhong Pharmaceutical Factory, was listed as a key pollutant discharge unit in Zhengzhou for 2022[185]. - The wastewater treatment facility at the company can process 1,000 tons of wastewater daily, utilizing a series of advanced treatment processes to ensure compliance with discharge standards[188]. - The company reported that all major pollutants, including SO2 and nitrogen oxides, from both its facilities met the emission standards[190]. - The company has received its pollution discharge permit as of July 2020, in compliance with national regulations[191]. Social Responsibility - Total charitable contributions amounted to 260,400 RMB, including donations to various charitable organizations and educational funds[200]. - The company donated 100,000 RMB to the Henan Charity Federation and 20,000 RMB to the Tonglu County Charity Federation[200]. - During the pandemic, the company provided anti-epidemic supplies to local communities, demonstrating its commitment to social responsibility[200].

2022 年第三季度报告 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人尹辉、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益 | 109,129.93 | 30,343.03 | | | 越权审批，或无正式批准文件，或偶发性的税收返还、 | | | | | 减免 | | | | | 计入当期损益的政府补助，但与公司正常经营业务密切 | | | | | 相 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 863,676,913.87, representing a year-on-year increase of 14.87%[18]. - The net profit attributable to shareholders decreased by 193.56% to a loss of CNY 25,432,310.28, primarily due to a decline in revenue from the pharmaceutical formulation business and legal compensation from a subsidiary[20]. - The net cash flow from operating activities decreased by CNY 66,380,836.05, reflecting a slowdown in sales collections due to the impact of the pandemic[20]. - The revenue from traditional Chinese medicine segment increased by 33.34% due to higher sales volume and price adjustments[19]. - The revenue from pharmaceutical research services grew by 25.34% driven by business expansion and capacity enhancement[19]. - The revenue from pharmaceutical formulation business declined by 23.41% due to restrictions on core product sales from pandemic control policies[19]. - The basic earnings per share for the first half of 2022 was -CNY 0.0452, a decrease of 193.20% compared to the same period last year[19]. - The weighted average return on net assets decreased by 3.23 percentage points to -1.51%[19]. - The company reported a non-recurring loss of approximately ¥10.1 million, primarily due to non-operating expenses and losses from financial instruments[23]. - The company achieved operating revenue of 863.68 million yuan, a year-on-year increase of 14.87%[41]. - The net profit attributable to shareholders was -25.43 million yuan, a decrease of 52.5 million yuan compared to the same period last year, primarily due to a decline in revenue from the pharmaceutical formulation business and litigation compensation payments[41]. Assets and Liabilities - The company's total assets decreased by 6.63% to CNY 3,532,867,336.33 compared to the end of the previous year[18]. - The net assets attributable to shareholders increased slightly by 0.03% to CNY 1,660,987,096.22[18]. - The company's cash and cash equivalents decreased by 57.48% to CNY 161,812,932.03 from CNY 380,549,308.28, attributed to slower sales collections and reduced bank financing[55]. - Long-term equity investments increased significantly by 315.24% to CNY 65,295,383.43, compared to CNY 15,724,611.04, indicating new investments in associated companies[55]. - The company's total liabilities decreased from ¥2,006,135,829.69 to ¥1,724,127,783.32, a decrease of approximately 14.0%[129]. - The company's total assets decreased from ¥3,783,772,407.22 to ¥3,532,867,336.33, representing a decline of about 6.6%[129]. Research and Development - The company has a research and development team of nearly 1,000 people, led by top domestic and international experts, and has advanced research and testing equipment, positioning it as a leader in R&D capabilities in the industry[40]. - The company processed over 4,200 tons of traditional Chinese medicine pieces and brewed 840,000 doses, further enhancing production and sales scale[42]. - The company participated in the research and development of nearly 123 projects, with 30 drug registration applications under review, including 2 innovative drugs and 18 improved new drugs[43]. - The company established a new R&D platform in Chongqing and Zhengzhou, enhancing its drug development service capabilities[45]. - The R&D team consists of 945 members, with 238 holding master's or doctoral degrees, accounting for 25.19%[45]. - Research and development expenses rose significantly by 57.40% to CNY 44,939,144.73, compared to CNY 28,550,211.51, as the company increased investment in product development[48]. Market and Business Strategy - The main business segments include pharmaceutical manufacturing, traditional Chinese medicine, and drug research and development services, with a focus on oral preparations and traditional Chinese medicine pieces[25]. - The pharmaceutical manufacturing segment features exclusive products such as the concentrated version of Shuanghuanglian oral liquid and pediatric formulations, contributing significantly to revenue[25]. - The drug research and development services are provided by a subsidiary, focusing on preclinical studies, clinical CRO research, and regulatory submissions, aimed at reducing R&D risks and timelines for clients[26]. - The company aims to expand its market presence by deepening relationships with existing clients and exploring new customer segments through professional marketing strategies[29]. - The company has leveraged its regional advantages to procure and sell traditional Chinese medicine and pharmaceuticals, enhancing its market position[31]. - The company has established a comprehensive supply chain for traditional Chinese medicine, ensuring quality and cost control through long-term partnerships with local farmers[28]. Environmental and Social Responsibility - The company has not experienced any environmental pollution incidents or received administrative penalties from environmental protection authorities during the reporting period[79]. - The company reported a chemical oxygen demand (COD) discharge concentration of 18-72 mg/l, with a total discharge of 0.445 tons in the first half of 2022, well below the permitted limit of 100 mg/l[80]. - The company has implemented an emergency response plan for environmental incidents, registered with the local environmental authority[85]. - The company promotes clean production and has established a standardized system for production and management, aiming to reduce waste generation and improve resource efficiency[93]. - The company has engaged in land circulation in medicinal material production areas, helping local farmers increase income and contributing to rural revitalization[94]. - The company utilizes natural gas as a clean energy source to reduce emissions of waste gas pollutants[92]. Corporate Governance and Shareholder Relations - The company held its first extraordinary general meeting on February 25, 2022, where five proposals were approved, including the reappointment of the accounting firm[67]. - The company reported no dividend distribution or capital reserve transfer plan for the first half of 2022, with no shares or cash dividends proposed[72]. - The company has implemented the second phase of its employee stock ownership plan in 2021, transferring 11,083,700 shares at a price of 4.49 CNY per share, with a lock-up period of 12 months[75]. - The company approved a share repurchase plan with a budget between 40 million RMB and 80 million RMB, with a maximum repurchase price of 7 RMB per share[116]. - The total number of ordinary shareholders as of the end of the reporting period was 41,394[118]. - The largest shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., held 82,441,168 shares, accounting for 14.37% of total shares[120]. Financial Reporting and Compliance - The financial statements are prepared in accordance with the enterprise accounting standards[165]. - The accounting period for the company runs from January 1 to December 31 each year[166]. - The company's accounting currency is Renminbi (CNY)[168]. - The company recognizes financial assets or liabilities when it becomes a party to a financial instrument contract[191]. - Financial assets are classified at initial recognition based on the company's business model and cash flow characteristics, including amortized cost, fair value through other comprehensive income, and fair value through profit or loss[192]. - The company assesses significant increases in credit risk by comparing the risk of default at the reporting date with the risk at initial recognition, considering adverse changes in business, financial, or economic conditions[199].

证券代码：600222 证券简称：太龙药业 编号：临 2022-036 河南太龙药业股份有限公司 关于参加河南辖区上市公司 2022 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强投资者的互动交流，河南太龙药业股份有限公司定 于 2022 年 5 月 30 日（周一）15:30-17:00 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2022 年投资者网上集体接待日 活动，本次活动将采用网络远程的方式举行，投资者可登录"全景·路 演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事长尹辉先生、 总经理罗剑超先生、董事会秘书冯海燕女士、财务负责人赵海林先生 （如有特殊情况，参会人员将可能进行调整），欢迎广大投资者积极 参与。 特此公告。 河南太龙药业股份有限公司董事会 2022 年 5 月 26 日 ...

Financial Performance - The company's operating revenue for Q1 2022 was CNY 422,282,414.89, representing a year-on-year increase of 1.52%[5] - The net profit attributable to shareholders of the listed company was CNY 2,329,695.73, showing a significant decrease of 91.33% compared to the same period last year[5] - The basic earnings per share (EPS) was CNY 0.0041, down 91.48% year-on-year[6] - Total revenue for Q1 2022 was CNY 422,282,414.89, a slight increase of 0.78% compared to CNY 415,958,437.10 in Q1 2021[22] - Net profit for Q1 2022 was CNY 2,166,570.19, a significant decrease of 91.86% from CNY 26,632,438.79 in Q1 2021[23] - The company's operating profit for Q1 2022 was CNY 2,976,218.24, down from CNY 30,641,135.93 in Q1 2021, indicating a decline of 90.31%[23] - Basic and diluted earnings per share for Q1 2022 were CNY 0.0041, down from CNY 0.0481 in Q1 2021, a decline of 91.49%[24] - Other comprehensive income for Q1 2022 was negative CNY 4,641,036.70, contrasting with a positive CNY 196,461,366.30 in Q1 2021[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,789,529,131.70, a slight increase of 0.15% from the end of the previous year[6] - The total assets as of Q1 2022 amounted to CNY 3,789,529,131.70, slightly up from CNY 3,783,772,407.22 at the end of Q1 2021[21] - Total liabilities for Q1 2022 were CNY 1,884,367,020.68, down from CNY 2,006,135,829.69 in Q1 2021, a decrease of 6.09%[21] - The company's total equity increased to CNY 1,905,162,111.02 in Q1 2022, compared to CNY 1,777,636,577.53 in Q1 2021, marking an increase of 7.16%[21] Cash Flow - The net cash flow from operating activities was negative at CNY -151,971,688.24, indicating a significant cash outflow[5] - Cash inflow from operating activities for Q1 2022 was $363.89 million, up from $312.19 million in Q1 2021, representing a 16.5% increase[26] - Net cash outflow from operating activities for Q1 2022 was -$151.97 million, compared to -$43.52 million in Q1 2021, indicating a significant decline[27] - Cash inflow from investment activities for Q1 2022 was $591.64 million, a substantial increase from $162.82 million in Q1 2021, marking a 263.5% rise[27] - Cash inflow from financing activities for Q1 2022 was $102.20 million, down from $165.15 million in Q1 2021, showing a decrease of 38.1%[27] - The ending cash and cash equivalents balance for Q1 2022 was $214.11 million, down from $493.69 million in Q1 2021, indicating a decline of 56.7%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,264[10] - The company’s major shareholder changed to Zhengzhou Tai Rong Industrial Investment Co., Ltd., which acquired 82,441,168 shares, accounting for 14.37% of the total share capital[13] - The company’s board of directors and supervisory board were restructured on February 25, 2022, with a new chairman elected[13] - The company’s repurchase account held 10,846,107 shares, representing 1.89% of the total shares as of the reporting period[12] Expenses and Investments - The decline in net profit was primarily due to the sales restrictions on four categories of drugs, leading to decreased revenue and gross profit[8] - The company faced increased sales expenses as it intensified market promotion for other product lines[8] - Research and development expenses increased to CNY 19,581,712.93 in Q1 2022, compared to CNY 14,409,179.35 in Q1 2021, reflecting a growth of 36.06%[23] - Non-recurring gains and losses amounted to a net loss of CNY -120,616.38 after tax adjustments[8] - The company received financial support of up to 1.2 billion RMB from its indirect controlling shareholder, with the first tranche of 419 million RMB already received[15] - The company’s long-term equity investments stood at 15,473,270.37 RMB as of March 31, 2022, slightly down from 15,724,611.04 RMB at the end of 2021[17] - The company’s total liabilities and equity structure will be impacted by the recent changes in major shareholders and financial support arrangements[13][15]

Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of RMB 5,995,375.55, a decrease of 79.50% compared to RMB 29,240,862.39 in 2020[5]. - The company's operating revenue for 2021 was RMB 1,604,516,940.00, representing a year-on-year increase of 13.23% from RMB 1,417,097,311.59 in 2020[21]. - The net cash flow from operating activities increased by 35.72% to RMB 99,655,159.11 in 2021, compared to RMB 73,427,546.30 in 2020[21]. - The total assets of the company as of the end of 2021 were RMB 3,783,772,407.22, an increase of 11.64% from RMB 3,389,394,715.08 at the end of 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 36,179,012.56, a significant increase of 159.11% compared to RMB 13,962,693.07 in 2020[21]. - Basic earnings per share (EPS) fell by 80.00% to RMB 0.0107, while diluted EPS remained the same[22]. - The weighted average return on equity (ROE) decreased by 1.73 percentage points to 0.37%[22]. - The company reported a significant loss of RMB 30.18 million from non-recurring gains and losses, impacting overall profitability[27]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.10 per share, totaling RMB 5,630,401.76, which accounts for 93.91% of the net profit attributable to shareholders for 2021[5]. - For the 2021 fiscal year, the company plans to distribute a cash dividend of CNY 0.10 per share (including tax), amounting to CNY 5,630,401.76, which represents 93.91% of the net profit attributable to shareholders of the parent company[172]. Business Growth and Strategy - The company's operating revenue increased by 13.23% year-on-year, driven by a 35.74% growth in pharmaceutical R&D services and a 19.31% increase in traditional Chinese medicine products[23]. - The company is focusing on expanding its market presence and enhancing brand promotion for its traditional Chinese medicine products[23]. - The company is actively expanding its market presence by integrating existing traditional Chinese medicine products and increasing marketing investments in targeted product combinations[34]. - The company aims to enhance product quality through strict adherence to production standards and quality management practices[49]. - The company is committed to expanding its market presence and enhancing brand influence through strategic partnerships and marketing initiatives[56]. Research and Development - The company has 906 personnel in the R&D team, with 23.62% holding master's or doctoral degrees, indicating a strong talent pool[36]. - The company has established multiple platforms for drug research, focusing on high-end formulations and innovative drug research, including preclinical and clinical trial services[57]. - The company has initiated 56 new research projects in high-end generic and innovative drugs, bringing the total number of ongoing projects to 267[103]. - The company is focusing on high-barrier therapeutic areas such as cardiovascular, anti-tumor, and digestive system drugs, aligning R&D efforts with market demand[103]. - The company is conducting clinical research on TLZ0005, a new drug for breast disease, which is currently in the clinical research phase[104]. Environmental Responsibility - The company was listed as a key pollutant discharge unit in Zhengzhou for 2021, with strict adherence to national standards for pollutant treatment and discharge[184]. - No environmental pollution incidents occurred during the reporting period, and the company did not face any administrative penalties from environmental protection authorities[185]. - The company has implemented a comprehensive environmental monitoring plan, with third-party testing confirming that all pollutants are within regulatory limits[192]. - The company emphasizes a low-carbon production philosophy, advocating for resource conservation and green practices among employees[197]. Governance and Management - The governance structure of the company is robust, ensuring compliance with laws and regulations while protecting shareholder interests[134]. - The company maintains transparent communication with investors, ensuring their rights are protected and fostering good investor relations[136]. - The company completed the election of the ninth board of directors and the ninth supervisory board on February 25, 2022, with new appointments including Yin Hui as chairman and Luo Jianchao as general manager[143]. - The company has proposed to allocate profits for the year 2020, indicating a focus on shareholder returns[139]. - The company has established a comprehensive human resources management system, including salary and welfare, performance evaluation, training management, and promotion systems[169]. Market Trends and Industry Insights - The Chinese CRO market is expected to grow at a compound annual growth rate (CAGR) of 20.22% from 2020 to 2030, reaching a market size of approximately 329.2 billion yuan by 2030[42]. - The global CRO market is projected to reach $168.9 billion by 2030, with a CAGR of 9.95% from 2020 to 2030[42]. - The pharmaceutical manufacturing industry achieved operating revenue of 2,928.85 billion yuan in 2021, growing by 20.1% year-on-year, indicating a robust industry trend[40]. - The ongoing reforms in the medical insurance system are expected to further support the development of TCM services and products[47]. Community Engagement - The company donated over 1.5 million yuan worth of medicines to support disaster relief efforts following severe flooding[198]. - The company aims to support rural economic development by promoting standardized planting techniques and processing projects for traditional Chinese medicine[199].